A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

So, I think that shows a lot promise.” The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids, which are often available as generics for ...

Most Advantage plans have a drug list, called a formulary. A person can check with their plan’s formulary to find out if Xarelto is covered. Medicare Part D covers prescription drugs.

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$ ...

By every measure, that spending is on the rise; by drug “list price,” the increase is astronomical—from $636 billion in 2018 to $917 billion in 2023. What exactly are PBMs saving us from ...

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday. Speaking on a panel at the World ...

Geoffrey Joyce, the director of Health Policy at the University of Southern California's Schaeffer Center for Health Policy & Economics, told Newsweek that the $2 Medicare drug list model that ...

That report lists three proposed models: the Medicare High-Value Drug List Model, the Cell & Gene Therapy Access Model and the Accelerating Clinical Evidence Model. The first model allows Part D ...

It’s true to say that drug usage has a variety of negative consequences for its users and, on the whole, governments are right to advise against it. People in New York who smoke cannabis should ...

China’s healthcare regulator has pledged to investigate the quality of drugs under a new list covered by national insurance, after policy advisers in Shanghai warned that they might be substandard.